Other biomarkers such as tumor mutational burden (TMB), inflammation, alteration in a specific gene or signalling pathway (e.g. BCL9 in Wnt pathway), APC mutation and MSI, allow stratification of patients for targeted immunotherapy and are consistent with several studies whereby TMB contributed to CRC immune landscape modelling (37); and BCL9 depletion in Wnt signalling reprogrammed TIME, promoting anti-tumoral immune response (60, 67, 69). This evidence concerns the gene BCL9 and neoplasm.